JENNIFER RIVAS: Open Payments
NPI 1740676352 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,918 in 92 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $417 · 2025 $1,918
Food & beverage: $1,833Education: $85
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $450 |
| Janssen Biotech, Inc. | 7 | $376 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 22 | $299 |
| Ardelyx, Inc. | 22 | $295 |
| QOL Medical, LLC | 3 | $169 |
| Aimmune Therapeutics, Inc. | 5 | $116 |
| Gilead Sciences, Inc. | 3 | $72 |
| Phathom Pharmaceuticals, Inc. | 4 | $45 |
| GENZYME CORPORATION | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
Products named: TREMFYA, XIFAXAN, IBSRELA, Sucraid, RINVOQ, CREON, ZENPEP, MAVYRET.
Industry payments across NY — which companies pay providers there.
